VF
CTMX icon

Virtu Financial’s CytomX Therapeutics CTMX Stock Holding History

Virtu Financial’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$479K Buy
+101,895
New +$517K 0.02% 592
2025
Q3 		– Sell
-35,136
Closed -$80K – 1576
2025
Q2 		$80K Buy
35,136
+23,339
+198% +$37.6K ﹤0.01% 1064
2025
Q1 		$8K Sell
11,797
-45,215
-79% -$35.1K ﹤0.01% 1205
2024
Q4 		$59K Sell
57,012
-31,506
-36% -$33.9K ﹤0.01% 1129
2024
Q3 		$104K Buy
+88,518
New +$112K 0.01% 901
2023
Q2 		– Sell
-24,136
Closed -$36K – 1603
2023
Q1 		$36K Buy
+24,136
New +$54.6K ﹤0.01% 1151
2022
Q1 		– Sell
-52,434
Closed -$227K – 1594
2021
Q4 		$227K Buy
+52,434
New +$307K 0.02% 773
2021
Q1 		– Sell
-14,051
Closed -$92K – 1663
2020
Q4 		$92K Buy
14,051
+986
+8% +$7.04K 0.01% 1083
2020
Q3 		$87K Buy
+13,065
New +$96.9K 0.01% 733
2018
Q2 		– Sell
-11,123
Closed -$316K – 2048
2018
Q1 		$316K Buy
+11,123
New +$317K 0.02% 1016
2017
Q4 		– Sell
-12,291
Closed -$223K – 2438
2017
Q3 		$223K Buy
+12,291
New +$192K 0.01% 1717

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Virtu Financial's CTMX Position: Q1 2026 in Review

Virtu Financial opened a new position in CytomX Therapeutics (CTMX) in Q1 2026: 101,895 shares worth $479K. The stake represents 0.02% of the portfolio and ranks #592 among its holdings. This is a return to the name: Virtu Financial previously reported a position in CTMX as recently as Q2 2025.

Virtu Financial first reported a position in CTMX in Q3 2017 and has held it in 11 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Virtu Financial held 101,895 shares of CytomX Therapeutics worth $479K as of Q1 2026.
  • CytomX Therapeutics was a new Virtu Financial position in Q1 2026.
  • CytomX Therapeutics made up 0.02% of Virtu Financial's portfolio in Q1 2026, its #592 holding.
  • Virtu Financial first reported a position in CytomX Therapeutics in Q3 2017 and has held it in 11 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.